跳至主要内容
临床试验/RBR-5q4gm5b
RBR-5q4gm5b招募中3 期

Double-blind, randomized, controlled study on the effect of Sacubitril/Valsartan in the prevention of cardiotoxicity in high-risk patients undergoing chemotherapy with anthracyclines

Hospital Erasto Gaertner0 个研究点开始时间: 2022年3月7日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • Patients diagnosed with cancer who will undergo chemotherapy with anthracyclines and who have an increase in ultrasensitive troponin I above the 99th percentile after any chemotherapy session; age over 18 years; patients who sign the Free and Informed Consent Term

排除标准

  • Inability to analyze ventricular function; claustrophobia; history of chemotherapy or radiotherapy; previous symptoms of heart failure; presence of cardiomyopathy ou coronary artery disease; moderate to severe aortic or mitral valve disease; contraindication to the use of Sacubitril/Valsartan such as a history of angioedema, renal artery stenosis; creatinine clearance <30ml/min/m2; serum potassium >5.0mEq/L; pregnant women; systolic blood pressure <100mmHg; use of angiotensin converting enzyme inhibitor, angiotensin receptor blocker, Sacubitril/Valsartan, or beta-blocker; implantation of pacemaker not compatible with MRI; patients with HER 2 expression; patients with frailty or at medium-high risk of hospitalization with substantial change in chemotherapy regimen

研究者

发起方
Hospital Erasto Gaertner

相似试验